Search results for " DEMENTIA"

showing 10 items of 165 documents

En kartlegging av teknologiske hjelpemidler til personer med nyoppdaget demens

2014

Masteroppgave i helse- og sosialinformatikk HSI 500 Universitetet i Agder 2014 The main objective of the national program of welfare technology is that welfaretechnological solutions will be an integrated part of the health and care services within 2020.Several projects in this program will include safety packages. Before technological tools areimplemented, a survey regarding the needs and challenges should be conducted. The presentstudy has focused on people with dementia and their relatives, because in 2040, the number ofpeople with dementia is expected to double.Welfare technological solutions can be divided into three parts: fall, isolation, and cognitiveimpairment. Thus, the current st…

HSI500VDP::Technology: 500::Information and communication technology: 550Velferdsteknologi demens trygghetspakke ; teknologiske hjelpemidler ; welfare technology ; dementia ; safety packages ; technological tools
researchProduct

Accuracy of the clinical diagnosis of dementia with Lewy bodies (DLB) among the Italian Dementia Centers: a study by the Italian DLB study group (DLB…

2022

Introduction: Dementia with Lewy bodies (DLB) may represent a diagnostic challenge, since its clinical picture overlaps with other dementia. Two toolkits have been developed to aid the clinician to diagnose DLB: the Lewy Body Composite Risk Score (LBCRS) and the Assessment Toolkit for DLB (AT-DLB). We aim to evaluate the reliability of these two questionnaires, and their ability to enhance the interpretation of the international consensus diagnostic criteria. Methods: LBCRS and AT-DLB were distributed to 135 Italian Neurological Centers for Cognitive Decline and Dementia (CDCDs), with the indication to administer them to all patients with dementia referred within the subsequent 3 months. We…

Lewy Body DiseaseClinical diagnosiDementia with Lewy bodieConsensus criteriaDementia with Lewy bodiesDermatologybehavioral disciplines and activitiesDiagnostic accuracyDiagnosis DifferentialAlzheimer DiseaseDiagnosismental disordersHumansReproducibility of ResultsDiagnostic toolkitGeneral MedicineClinical diagnosis; Cognitive impairment; Consensus criteria; Dementia; Dementia with Lewy bodies; Diagnostic accuracy; Diagnostic toolkitsClinical diagnosisnervous system diseasesSettore MED/26 - NEUROLOGIAPsychiatry and Mental healthCognitive impairmentItalyDifferentialDiagnostic toolkitsDementiaNeurology (clinical)
researchProduct

DCTN1 mutation analysis in Italian patients with PSP, MSA, and DLB

2020

Abstract DCTN1 encodes the largest subunit of dynactin complex essential in the retrograde axonal transport and cytoplasmic transport of vesicles; mutations in DCTN1 have been reported predominantly in individuals with Perry syndrome and, recently, in patients with progressive supranuclear palsy. Our genetic screening of DCTN1 in 79 patients with progressive supranuclear palsy, 100 patients with multiple system atrophy, and 28 patients with dementia with Lewy bodies from Italy revealed only synonymous and intronic variants, suggesting that DCTN1 mutations do not have a key role in the development of atypical parkinsonism in the Italian population.

Lewy Body DiseaseMale0301 basic medicineAgingPathologymedicine.medical_specialtyDementia with Lewy bodieDNA Mutational AnalysisDynactinProgressive supranuclear palsy03 medical and health sciences0302 clinical medicineAtrophymedicineHumansIn patientGenetic TestingGenetic Association StudiesAgedDCTN1Dementia with Lewy bodiesbusiness.industryProgressive supranuclear palsyGeneral NeuroscienceParkinson DiseaseDynactin ComplexMiddle AgedMultiple System Atrophymedicine.diseaseDCTN1030104 developmental biologyItalyMutation testingDynactinAxoplasmic transportDCTN1; Dementia with Lewy bodies; Dynactin; Multiple system atrophy; Progressive supranuclear palsyFemaleSupranuclear Palsy ProgressiveNeurology (clinical)Geriatrics and GerontologybusinessNegative Results030217 neurology & neurosurgeryDevelopmental BiologyNeurobiology of Aging
researchProduct

Survival time and differences between dementia with Lewy bodies and Alzheimer’s disease following diagnosis: a meta-analysis of longitudinal studies.

2019

Objective: To synthesize the evidence across longitudinal studies comparing survival in dementia with Lewy bodies (DLB) and Alzheimer's disease (AD). Methods: We conducted a systematic review and meta-analysis of studies comparing survival in clinically diagnosed DLB to AD. Longitudinal cohort studies were identified through a systematic search of major electronic databases from inception to May 2018. A random effects meta-analysis was performed to calculate survival time and relative risk of death. Results: Overall, 11 studies were identified including 22,952 patients with dementia: 2029 with DLB (mean diagnosis age 76.3; 47% female) compared with 20,923 with AD (mean diagnosis age 77.2; 6…

Lewy Body DiseaseMale0301 basic medicineAgingmedicine.medical_specialtyDiseaseBiochemistryLewy bodie03 medical and health sciences0302 clinical medicineA meta-analysis of longitudinal studies.- Ageing research reviews cilt.50 ss.72-80 2019 [MUELLER C. Soysal P. RONGVE A. ISIK A. THOMPSON T. MAGGI S. SMITH L. Basso C. STEWART R. BALLARD C. et al. -Survival time and differences between dementia with Lewy bodies and Alzheimer-s disease following diagnosis]Alzheimer DiseaseInternal medicinemental disordersmedicineHumansDementiaLongitudinal StudiesLongitudinal cohortMortalityMolecular BiologyAgedDementia with Lewy bodiesbusiness.industryCognitive scoreAlzheimer's diseaseRandom effects modelmedicine.diseaseSurvival RateObservational Studies as Topic030104 developmental biologyNeurologyMeta-analysisRelative riskFemaleDementiabusinessLewy bodiesAlzheimer’s disease030217 neurology & neurosurgeryBiotechnology
researchProduct

Neuropsychiatric symptoms in 921 elderly subjects with dementia: a comparison between vascular and neurodegenerative types.

2008

Objective:  i) to describe the neuropsychiatric profile of elderly subjects with dementia by comparing vascular (VaD) and degenerative dementias, i.e. dementia with Lewy bodies (DLB) and Alzheimer’s disease (AD); ii) to assess whether the severity and type of dementia are associated with clinically relevant neuropsychiatric symptoms (CR-NPS). Method:  One hundred and thirty-one out-patients with VaD, 100 with DLB and 690 with AD were studied. NPS were evaluated by the neuropsychiatric inventory (NPI). Results:  Vascular dementia had lower total and domain-specific NPI scores and a lower frequency of CR-NPS than AD and DLB, for which frequency of CR-NPS increased significantly with disease s…

Lewy Body DiseaseMalemedicine.medical_specialtyPathologyPsychometricsDiseaseNeuropsychological TestsCentral nervous system diseaseDegenerative diseaseAlzheimer DiseaseInternal medicinemental disordersmedicineDementiaHumansVascular dementiaAgedAged 80 and overLewy bodyDementia with Lewy bodiesDementia Vasculartechnology industry and agricultureReproducibility of Resultsneuropsychiatric symptoms vascular dementia dementia with Lewy bodies Alzheimer’s disease dementia severitymedicine.diseasePsychiatry and Mental healthnervous systemDisease ProgressionSettore MED/26 - NeurologiaFemaleAlzheimer's diseasePsychologyActa psychiatrica Scandinavica
researchProduct

Analysis of the LRP10 gene in patients with Parkinson's disease and dementia with Lewy bodies from Southern Italy

2020

Recently, the LRP10 gene has been associated with Parkinson's disease (PD), Parkinson's disease with dementia (PDD), and dementia with Lewy bodies (DLB). The aim of the present study was to evaluate the presence of mutations of the LRP10 gene in patients with PD or DLB from Southern Italy. Sequencing analysis revealed only 2 missense and 3 synonymous variants in patients and control subjects and a rare variant p.L622F in a PD case. These results suggest that LRP10 mutations are not a frequent cause of PD and DLB in Southern Italy.

Lewy Body Diseasemedicine.medical_specialtyNeurologyParkinson's diseaseLRP10 . Parkinson’s disease . Dementia with Lewy bodiesDermatologyDiseasebehavioral disciplines and activities03 medical and health sciences0302 clinical medicineAlzheimer DiseaseInternal medicineDementia with Lewy bodies; LRP10; Parkinson's disease.mental disordersmedicineDementiaMissense mutationHumans030212 general & internal medicineNeuroradiologyDementia with Lewy bodiesbusiness.industryParkinson DiseaseGeneral Medicinemedicine.diseasenervous system diseasesPsychiatry and Mental healthItalyMutationSettore MED/26 - NeurologiaNeurology (clinical)Neurosurgerybusiness030217 neurology & neurosurgery
researchProduct

The Italian dementia with Lewy bodies study group (DLB-SINdem): toward a standardization of clinical procedures and multicenter cohort studies design

2017

Dementia with Lewy bodies (DLB) causes elevated outlays for the National Health Systems due to high institutionalization rate and patients' reduced quality of life and high mortality. Furthermore, DLB is often misdiagnosed as Alzheimer's disease. These data motivate harmonized multicenter longitudinal cohort studies to improve clinical management and therapy monitoring. The Italian DLB study group of the Italian Neurological Society for dementia (SINdem) developed and emailed a semi-structured questionnaire to 572 national dementia centers (from primary to tertiary) to prepare an Italian large longitudinal cohort. The questionnaire surveyed: (1) prevalence and incidence of DLB; (2) clinical…

Lewy Body Diseasemedicine.medical_specialtyPediatricsDementia with Lewy bodieDementia with Lewy bodiesDermatologyCohort StudiesDiagnosis Differential03 medical and health sciences0302 clinical medicineQuality of lifeAlzheimer DiseaseSurveys and Questionnairesmental disordersStandardization of diagnostic proceduresDiagnosisDementia with Lewy bodies; Standardization of diagnostic procedures; Survey; Alzheimer Disease; Cohort Studies; Diagnosis Differential; Disease Management; Humans; Italy; Lewy Body Disease; Research Design; Surveys and Questionnaires; 2708; Neurology (clinical); Psychiatry and Mental HealthmedicineDementiaHumans030212 general & internal medicineSurveyMED/01 - STATISTICA MEDICAMED/26 - NEUROLOGIAbusiness.industryDementia with Lewy bodiesDisease ManagementStandardization of diagnostic procedureGeneral Medicinemedicine.diseaseSettore MED/26 - NEUROLOGIADementia with Lewy bodies; Standardization of diagnostic procedures; Survey; 2708; Neurology (clinical); Psychiatry and Mental HealthItalyResearch DesignPsychiatry and Mental HealthCohortDifferentialPhysical therapyDeliriumNeurology (clinical)Alzheimer's diseasemedicine.symptombusiness030217 neurology & neurosurgeryFrontotemporal dementiaCohort study2708
researchProduct

Measuring network disruption in neurodegenerative diseases: New approaches using signal analysis

2019

Advanced neuroimaging has increased understanding of the pathogenesis and spread of disease, and offered new therapeutic targets. MRI and positron emission tomography have shown that neurodegenerative diseases including Alzheimer’s disease (AD), Lewy body dementia (LBD), Parkinson’s disease (PD), frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) are associated with changes in brain networks. However, the underlying neurophysiological pathways driving pathological processes are poorly defined. The gap between what imaging can discern and underlying pathophysiology can now be addressed by advanced techniques that explore the cortical neural synchro…

Lewy Body Diseasemedicine.medical_treatmentElectroencephalographysurgery03 medical and health sciences0302 clinical medicineNeuroimagingAlzheimer DiseasemedicineDementiaHumans1506Amyotrophic lateral sclerosisNeurodegeneration030304 developmental biologyneurology (clinical)0303 health sciencesLewy bodymedicine.diagnostic_testbusiness.industryAmyotrophic Lateral Sclerosissurgery; neurology (clinical); psychiatry and mental healthMagnetoencephalographyElectroencephalographyNeurodegenerative DiseasesParkinson DiseaseMagnetoencephalographymedicine.diseaseTranscranial Magnetic Stimulation3. Good healthTranscranial magnetic stimulationpsychiatry and mental healthFrontotemporal DementiaNerve NetbusinessNeuroscience030217 neurology & neurosurgeryFrontotemporal dementiaJournal of Neurology, Neurosurgery, and Psychiatry
researchProduct

Assessing natural metalinguistic skills in people with Alzheimer’s disease and frontotemporal dementia

2019

Abstract Objective The aim of this paper is to assess whether the use of natural metalinguistic skills can be used to differentiate linguistic-communicative profiles of people with dementia (Alzheimer’s disease and frontotemporal dementia in the behavioural and primary progressive aphasia variants) in the earliest stages of the disease. Method A sample of 180 people was selected. Sixty had Alzheimer’s disease, 20 had frontotemporal dementia of the behavioural variant, and 40 had frontotemporal dementia of the primary progressive aphasia variant (20 had non-fluent primary progressive aphasia and 20 had semantic dementia). The control group was composed of 60 healthy people with ages, gender,…

Linguistics and LanguageCognitive NeuroscienceSemantic dementiaLinguisticsExperimental and Cognitive PsychologyDiseaseNeuropsychological TestsLPN and LVNmedicine.diseaseAdditional researchTest (assessment)Primary progressive aphasiaSpeech and HearingAphasia Primary ProgressiveAlzheimer DiseaseFrontotemporal Dementiamental disordersmedicineHumansDementiaInternal validityPsychologyFrontotemporal dementiaClinical psychologyJournal of Communication Disorders
researchProduct

The relationship between Polypharmacy and Trajectories of Cognitive Decline in People with Dementia: a large representative cohort study

2019

Polypharmacy, defined through the number of medications prescribed, has been linked to a range of adverse health outcomes in people with dementia. It is however unclear whether a numerical threshold of concurrently prescribed drugs is a suitable predictor for cognitive decline. We aimed to test associations between polypharmacy and both short-term (six months) and long-term (three years) cognitive trajectories in patients with incident dementia. Using data from a large mental health and dementia care database in South London, a cohort of 12,148 patients (mean age = 80.7 years, 61.1% female, mean MMSE = 18.6) clinically diagnosed with dementia was identified. We determined the number of medi…

Male0301 basic medicineGerontologyAgingCognitive declineBiochemistryCohort Studies03 medical and health sciencesCognitionCommunity care0302 clinical medicineEndocrinologyA large representative cohort study.- Experimental gerontology cilt.120 ss.62-67 2019 [Soysal P. Perera G. Isik A. Onder G. Petrovic M. Cherubini A. Maggi S. Shetty H. Molokhia M. Smith L. et al. -The relationship between polypharmacy and trajectories of cognitive decline in people with dementia]mental disordersGeneticsmedicineHumansDementiaCognitive DysfunctionCognitive declineassociations between polypharmacyMolecular BiologyAgedAged 80 and overPolypharmacypeople with dementia.Mini–Mental State Examinationmedicine.diagnostic_testbusiness.industryCognition; Cognitive decline; Community care; Dementia; PolypharmacyCognitionlong-term (three years)Cell BiologyMental Status and Dementia Testsmedicine.diseaseComorbidity030104 developmental biologyCohortPolypharmacyFemaleDementiabusinessshort-term (six months)030217 neurology & neurosurgeryCohort study
researchProduct